Brenntag SE

Brenntag SE (BNR.XETRA) — 2021–2026 factual timeline (latest price EUR 55.9 as of 2026‑07‑07)

2021

Record financial year with sales of EUR 14,382.5m, operating gross profit of EUR 3,379m, operating EBITDA of EUR 1,344.6m, and EPS of EUR 2.90. Project Brenntag transformation made material progress and contributed to margin uplift [28, 31, 29]. The market viewed Brenntag as a beneficiary of recovery, favourable pricing, and successful transformation—a higher-margin, scalable chemical distributor positioned as a growth compounder [28, 31]. The share trended clearly upward through the year, closing at EUR 79.58 [28].

2022

Exceptional results: sales of EUR 19,429.3m, operating gross profit of EUR 4,319.0m, operating EBITDA of EUR 1,808.6m, operating EBITA of EUR 1,511.7m, and EPS of EUR 5.74. Management announced a dividend increase and a share buyback program of up to EUR 750m alongside the results, with "Strategy to Win" layered on top of transformation momentum [54]. Peak-cycle earnings and capital return dominated investor sentiment, though debate emerged about whether the cycle-driven earnings reflected structural margin gains or were unsustainable [54]. Despite record results, the share proved volatile and closed materially below 2021 levels at EUR 59.72, signalling a derating phase [44, 54].

2023

Sales of EUR 16,815.1m, operating gross profit of EUR 4,041.8m, operating EBITA of EUR 1,265.0m, and record free cash flow of EUR 1,712.0m. The buyback program remained active and management highlighted free-cash-flow strength [52, 53, 54]. Investors began reframing the stock as a very cash-generative, resilient distributor—a defensive compounder delivering shareholder returns through buybacks [52, 53]. A strong rally unfolded through 2023, with an annual high of EUR 83.22 on 29 December as sentiment turned positive on cash generation and buybacks [44, 52].

2024

Sales of EUR 16.24bn, operating gross profit of EUR 4.03bn, and operating EBITA of approximately EUR 1.10bn. Management completed approximately EUR 570m in acquisitions across eight closed deals. FY2025 operating EBITA was initially guided at EUR 1.1–1.3bn [4]. The narrative shifted from momentum to normalization as macro and geopolitical uncertainties pressured volumes and pricing; focus moved to acquisition execution and margin protection [4]. The share experienced a large correction through 2024, marking a pronounced negative annual return and a de-risking year [47, 4].

2025

Q1 showed gross-profit improvement but persistent weak end-market demand. After Q3, management lowered the annual operating EBITA forecast from EUR 1.1–1.3bn to EUR 950–1,050m and subsequently guided toward the lower end [25, 3]. Full-year results showed sales of EUR 15,171.5m, operating gross profit of EUR 3,831.7m, and operating EBITA of EUR 929.3m (down year-on-year); profit after tax was materially lower, free cash flow reached approximately EUR 940.8m, and the dividend proposal was reduced to EUR 1.90 [5, 11, 12]. M&A transactions signed or closed totaled approximately EUR 260m [11].

Christian Kohlpaintner announced he would not renew his term and stepped down effective 31 August; Jens Birgersson was appointed CEO effective 1 September, with further board and divisional changes following into late 2025 [13, 22, 20, 14, 15].

The narrative shifted materially from a cash-compounder and growth story to one focused on "operational reset and cost discipline," with concern about weaker end markets driving a return to emphasis on margins, cost savings, and execution under new leadership [3, 11, 16]. The year proved volatile: an annual high of EUR 68.24 on 6 March was followed by a sharp breakdown tied to the guidance cut and earnings weakness, with an annual low of EUR 46.26 on 11 November and a year-end close of EUR 49.56—a large drawdown from the December 2023 peak of EUR 83.22 [37, 44, 3, 11].

2026 (YTD through 2026‑07‑07)

Management completed the FY2025 reporting cycle and publicly accelerated cost measures and resilience actions to address weak markets; the new CEO signalled operational priorities and cost discipline as central to near-term execution [10, 16]. The market is watching execution of cost measures, M&A integration, and whether margins and stable cash flow recover under the new CEO, viewing the stock more as a recovery and execution trade in the near term [10, 16]. A partial recovery from the November 2025 low unfolded into mid-2026, with the price at EUR 55.9 as of 2026‑07‑07 representing a rebound and consolidation in the mid-50s after the 2023–2025 volatility and post-November 2025 trough [37, 44].